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Abstract
Background: Colonoscopy (CSPY) for colorectal cancer screening has several limitations. Colon Capsule Endoscopy 
(PillCam Colon, CCE) was compared to CSPY under routine screening conditions.
Methods: We performed a prospective, single-center pilot study at a University Hospital. Data were obtained from 
November 2007 until May 2008. Patients underwent CCE on Day 1 and CSPY on Day 2. Outcomes were evaluated 
regarding sensitivity and specificity of polyp detection rate, with a significance level set at >5 mm.
Results: 59 individuals were included in this study, the results were evaluable in 56 patients (males 34, females 22; 
median age 59). CCE was complete in 36 subjects. Polyp detection rate for significant polyps was 11% on CSPY and 
27% on CCE.
6/56 (11%) patients had polyps on CSPY not detected on CCE (miss rate).
Overall sensitivity was 79% (95% confidence interval [CI], 61 to 90), specificity was 54% (95% CI, 35 to 70), positive 
predictive value (PPV) was 63% and negative predictive value (NPV) was 71%. Adjusted to significance of findings, 
sensitivity was 50% (95% CI, 19 to 81), specificity was 76% (95% CI, 63 to 86), PPV was 20% and NPV was 93%.
Conclusion: In comparison to the gold standard, the sensitivity of CCE for detection of relevant polyps is low, however, 
the high NPV supports its role as a possible screening tool.
Trial Registration: NCT00991003.
Background
The incidence of colorectal cancer [(CRC), standardized
to age and world population] is 20-45/100.000 for men
und 15-30/100.000 for women[1]. It is increasing with
age[2] and the cumulative lifetime risk both for men and
for women arises to 6%[3]. Regardless of much improved
diagnostics, 50% of patients with CRC die from it. The
majority (90%) of CRC develop from benign adenoma-
tous polyps. Current evidence points to the important
role of screening colonoscopy with subsequent polypec-
tomy (CSPY), reducing the risk of developing CRC by 76-
90%[4-6]. Also, early recognization and removal of carci-
nomatous lesions is crucial, as 5-year survival rates for
DUKES stage A (UICC 0 to 1) are above 90%, whereas
overall 5-year-survival rate is 62%[7].
Screening guidelines recommending CSPY every 10
years for asymptomatic patients above 50 years with neg-
ative family history have been established in several Euro-
pean countries (eg. France, Italy, Germany) as well as in
the United States in order to detect polyps and prevent
progression into cancer[4,8,9]. Nevertheless, the average
miss rates vary from 13% to 27%[10,11] (adenoma ≤1 cm),
and around 5% for carcinoma[10]. Moreover, CSPY is an
investigator-dependent and risk-bearing (risk of perfora-
tion 0.18%, with polypectomy 0.32%)[12] procedure,
which requires adequate bowel preparation in order to be
cost-effective[13]. Patient acceptance remains the main
limiting factor to wide distribution of screening. Correct
compliance for screening was observed in 37.1% of sub-
jects and 62.9% for a single CSPY ever in life (retrospec-
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yearly sigmoidoscopy or 10-yearly CSPY)[14].
For the reason of limited resources, in Switzerland, to
date, CRC screening is not regularly promoted by the
health-care system[15,16].
Taking all of the above mentioned into account, Colon
capsule endoscopy (CCE; PillCam Colon®, Given Imaging
Ltd., Yoqneam, Israel) might be a novel method for the
screening of large populations.
As a further development to the well established Pill-
CamSB®, two wide-angle cameras provide an extended
view of lesions.
Two previous feasibility studies have shown its possible
value for tertiary care centers in a study setting[17,18] as
well as practicability in a private practice[19], however, a
recent multicenter study evaluating both detection of
polyps as well as cancer detected a limited sensitivity[20].
We report the findings of a single center study comparing
the performance of CCE with CSPY for the detection of
colorectal polyps and cancer.
Methods
Study design
This was a prospective, single center pilot analysis com-
paring the efficacy of CCE against routine screening
colonoscopy at a tertiary care center (University Hospital
of Basel, Switzerland). Patient enrolment was from
November 5, 2007, to May 7, 2008. All patients provided
written informed consent. The study was approved by the
Ethics Committee and registered at http://www.clinical-
trials.gov (NCT00991003). The study was partly funded
by the Nycomed Fund of the University Hospital Basel,
Switzerland and by Given Imaging Ltd., Yoqneam,
Israel.The authors designed the study, gathered and ana-
lyzed the data; the sponsors did not participate in design
or conduct of the study nor did they review or approve
the data.
Patients and Data Collection
Every patient who presented at or was referred to our
center was considered. Men and women above the age of
50 years without symptoms (indication for screening) or
with lower gastrointestinal signs and symptoms and indi-
viduals younger than 50 years with positive family history
for CRC, minimum 18 years were included in this study.
Exclusion criteria were CRC in the patient's history, car-
diac pacemaker, contraindications for sodium phosphate
solution (Colophos®) and risk factors for capsule retention
including surgical intestinal anastomosis, Crohn's Dis-
ease, diverticulitis and radiologically suspected bowel
obstruction.
General patient characteristics were assembled, includ-
ing demographics, family history and recent surgery, as
well as bowel habits. Patient acceptance was assessed
with a 5-item questionnaire upon completion of the sec-
ond examination (Table S1, additional file 1).
Adverse events were recorded on days 1 and 2 of the
study. Additionally, some technical data such as com-
pleteness of the examinations (inspection of the whole
large intestine from ileocoecal valve to anus), colon tran-
sit time, location of the capsule at the time of the first
Colophos® booster dose and capsule excretion were
recorded.
Study Definitions and Outcomes
The aim was to evaluate this novel method (CCE) for per-
formance as a screening tool compared to CSPY in
asymptomatic patients under routine screening condi-
tions. The proclaimed benefit would be an increase in
acceptance of screening for CRC and an augmented
detection rate of adenoma and/or carcinoma. Signifi-
cance was defined as polyp size >5 mm, with the hypoth-
esis that detection rate on CCE corresponds with results
of CSPY. The primary endpoint was the number of can-
cerous lesions and polyps detected on CCE compared to
CSPY. Secondary endpoints were completeness of the
exam, patient acceptance and adherence to preparation
regimen. Subanalyses regarding effect of bowel prepara-
tion on polyp detection on CCE and accuracy of detec-
tion with respect to histopathology were performed.
Interventions
Patients underwent CCE on day 1 and CSPY on day 2.
The examinations were carried out by different physi-
cians, with blinding of results until both examinations
had been completed and until interobserver evaluation
was finished. CSPY was performed by one of eight differ-
ent gastroenterologists and intubation of the terminal
ileum was not required. CCE was read by two of two gas-
troenterologists at our department. Segmental unblind-
ing was not feasible as the study was performed during
the routine setting at a University Hospital.
The PillCam® Colon Capsule is 11 mm × 31 mm in size
(Figure 1). It is equipped with two wide-angle (156°) cam-
eras acquiring pictures from both ends of the capsule at a
rate of 4 frames per second (2 pictures per second and
Figure 1 Original size of PillCam® Colon Capsule 11 mm × 31 mm
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age removal. A sleeping mode of 1 hour 45 minutes is
entered upon 10 minutes after ingestion. Detailed proce-
dure has been described elsewhere. Data analysis was
performed using RAPID software.
The capsule video was read in three steps: identifica-
tion of anatomical sites was done during "Quick View
Mode" at a rate of 20 frames per second. In a second and
third step the pictures were read at approximately 8
frames per second as described before. CCE was read
only once in order to simulate a routine clinical setting.
Detected lesions were reviewed by an additional physi-
cian who assessed their presence, size and localisation,
with consecutive interobserver agreement.
Standard CSPY with or without polypectomy was per-
formed under Propofol sedation using existing hospital
protocols for preparation, and procedural and post-pro-
cedural care[21].
Polyps were estimated by size (greater than 5 mm, ≤5
mm) and location (right or left hemicolon). Polyps
detected on CSPY were removed and histologically exam-
ined. Other pathologies such as diverticulae, angioectasia
and hemorrhoids and their location were also noted but
not considered as relevant.
Colon Preparation, Level of Cleansing and Propulsion of the 
Capsule
For colon cleansing we applied our department's standard
preparation procedure for CSPY including low-fibre diet
and Macrogolum (PEG, Cololyt®; Spirig Pharma, Egerkin-
gen, Switzerland), and added an oral motility agent
(Motilium®; Janssen-Cilag AG, Baar, Switzerland), Phos-
pho Soda-boosters (Colophos®; Spirig Pharma, Egerkin-
gen, Switzerland) and a suppository (Bisacodylum 10 mg,
Prontolax®; Streuli Pharma, Uznach, Switzerland), Table
1.
Quality of colon preparation was assesed using a 3
point scale in both CCE and CSPY, Table 2.
Statistical analysis
CCE was compared to CSPY which was considered to be
the gold standard. As this is a pilot study, calculation
regarding statistical power did not apply. Sensitivity,
specificity, positive predictive value and negative predic-
tive value were calculated per patient, for the included
number of patients (n = 56). Percentage values were
rounded to the nearest full number. Examinations were
excluded from statistical analysis if the capsule had not
reached the colon during the recording time. The equiva-
lence between the results of CCE and CSPY was calcu-
lated using Wilcoxon signed-rank test and χ2-test. A p-
value < 0.05 was considered statistically significant. Base-
line characteristics, cause of referral, colonoscopic and
capsule-endoscopic findings, technical data and results of
the patient questionnaire were documented on a
datasheet using Excel (Microsoft, Redmont, Washinton,
USA). Statistical analyses were performed using SPSS
software package (SPSS Inc., Chicago, Illinois, USA).
Results
Patients' characteristics
A total of 59 Patients were enrolled in this study. Three
patients had to be excluded from the data analysis
because the capsule did not reach the colon during exam-
ination time (1 remained in stomach, 2 in small bowel).
The exams of 56 patients (34 male, 22 female, mean age
60 years, median 59 years, range 38-84 years, 86% 50
years or older) were analyzed, indications are shown in
table 3.
Table 1: Summary of bowel preparation
Time (hours) Action
Day -3
all day Low-fibre diet
Day -2
all day liquid diet
Day -1
all day clear liquids only
18:00-19:30 2 Liters of Cololyt® (1 cup every 10-15 minutes)
Exam day
7:00-8:30 2 Liters of Cololyt® (1 cup every 10-15 minutes)
11:00 20 mg Domperidone (Motilium®) with a cup of 
water
11:15 Ingestion of PillCam® Colon with a cup of 
water
until 13:00 no food/liquid ingestion
13:00 Real time view assessment if capsule left 
stomach, then Booster dose of 45 ml 
Colophos® + 1 liter of water
17:00 Real time view assessment if capsule left 
stomach, then Booster dose of 30 ml 
Colophos® + 1 liter of water *)
19:30 10 mg Bisacodylum rectal suppository *)
22:00 End of examination
Day +1 Conventional colonoscopy
*) This action was taken only if PillCam® Colon 
had not been excreted by this time.
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The capsule was excreted within 10 hours after ingestion
and within battery duration in 36 patients (64%). In 2
(4%) cases wake-up was too late (past the ileocoecal
valve) and in 2 (4%) transmission interference occurred
from capsule to data recorder, probably due to external
interference (multiple nominations). The mean colon
recording time in the 36 complete examinations was 3
hours 9 minutes (median 2 hours 48 minutes). Mean and
median transmission times in all 56 subjects were 4 hours
35 minutes and median 4 hours 52 minutes, respectively.
CSPY was complete in all 56 patients, with a rate of 68%
(n = 38) for intubation of the terminal ileum.
Colon Preparation
Level of cleansing on CCE was good in 15 (27%), moder-
ate in 30 (54%) and poor in 11 (20%) cases. On CSPY, 7
(13%) subjects were well prepared, 38 (68%) moderately
and 11 (20%) poorly. 34 (61%) of the patients were
reported to have the same cleansing level in both
colonoscopy and CCE, 22 (39%) had different cleansing
levels in both examinations.
Polyp detection
Polyp detection rate (per-patient) was 50% (n = 28) for
CSPY and 62% (n = 35) for CCE. Significant size polyps
were diagnosed in 6 patients (11%) on CSPY, resp. 15
patients (27%) on CCE. 11% (n = 6) patients had polyps of
any size on CSPY that were not detected on CCE (miss
rate) (Wilcoxon signed-rank test p > 0.05: not signifi-
cant).
13/56 (23%) patients had findings of any size on CCE
that were not verified on CSPY, 2 (4%) were of significant
size. Patients did not undergo repeat colonoscopy.
For polyps of any size, CCE showed a sensitivity of 79%
(95% CI, 61 to 90), specificity 54% (95% CI, 35 to 70), PPV
of 63% and NPV of 71% for polyps of any size. For overall
polyp size, detection of polyps on CCE and on CSPY was
independent with statistical significance (p = 0.013) on
Pearson's χ2-Test, indicating differences in the detection
rate for polyps on both examinations (nominal data). For
relevant polyps (>5 mm) there was a correspondence in
the detection rates of both methods (p > 0.05). The sensi-
tivity was 50% (95% CI, 19 to 81), the specificity was 76%
(95% CI, 63 to 86), the PPV was 20% and the NPV was
93%, Table 4.
Presentation of different size-polyps on CCE/CSPY is
shown in Figure 2.
Effect of cleansing level on polyp detection
To assess whether the cleansing level determined accu-
racy of polyp detection, we subanalyzed the 15 (27%)
patients classified as good cleanliness level and the 11
(20%) with a pooply prepared bowel. Sensitivity did not
differ significantly in respect to cleansing, although PPV
and NPV were both 100% in good bowel preparation.
Analysis according to histopathology
Subanalysis with respect to histopathology revealed
excellent sensitivity for CCE for detection of significant
size tubular and tubulo-villous adenoma.
Per-patient-prevalence of adenoma was 27% (n = 15) on
CSPY. Numbers are too small to calculate for sensitivity
and specificity, but all (n = 3) of the detected tubulo-vil-
lous adenoma were detected by CCE. Tubular adenoma
were detected in 18% (a total of 10 patients on CSPY, all
size), one the two detected tubular adenoma of significant
size on CSPY was classified as ≤5 mm on CCE. One of the
two detected serrated adenoma was not seen on CCE.No
high-grade dysplasia or cancerous lesion was found on
either type of examination. Overall prevalence of hyper-
plastic polyps was 23% (n = 13). A detailed analysis
regarding number, size, location and histology of polyps
is shown in Table S6 (additional file 2).
Adverse events
One patient had an allergic skin reaction to the adhesive
tape of the electrodes during CCE. One patient presented
with abdominal pain after polypectomy (during CSPY). A
colonic perforation was ruled out.
Patients' acceptance
Patients' acceptance was assessed from the given ques-
tionnaires. Out of a total of 56 questionnaires, 53 (95%)
Table 2: Description of colon cleansing level
Grade Description
1 clean, small amount of feces/dark fluid, good 
assessability
2 moderate preparation due to remaining feces/dark 
fluid, limited assessability but clean enough to 
preclude significant lesions
3 poor preparation, enough feces/fluid to strongly 
limit assessability
Table 3: Indications/symptoms (n = 56)
Screening 23 (41%)
Family history 4 (7%)
Follow-up after polypectomy 3 (5%)
Abdominal pain 8 (14%)
Bleeding frank 8 (14%)
Anemia 2 (4%)
Change in bowel habits 6 (11%)
Diarrhea 1 (2%)
Weight loss 1 (2%)
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the capsule. 16 patients (30%) felt restricted during daily-
life activities by carrying the electrodes and the recorder.
21 (40%) patients preferred CCE to CSPY, while 20 (38%)
preferred CSPY and 12 (23%) had no preference.
Also, 50 (94%) patients would recommend CCE. 44
(83%) subjects would prefer to undergo a capsule
colonoscopy again in ten years' time for screening pur-
poses compared to 8 patients (15%) who declined and 1
patient (2%) who was indecisive.
Discussion
Overall, this single center pilot trial comparing CCE to
CSPY for screening of colorectal cancer showed feasible
results in imaging for colonic polyps.
Detection rate of polyps of any size on CSPY was 50%,
with an adenoma detection rate of 27% (any size).Those
are comparable to a large prospective, community-based
study[22].
For the primary endpoint, CCE had a low sensitivity
(50%). The used size graduation for significance (as
defined as >5 mm in our study and >6 mm/>3 polyps of
any size in the previous two pilot studies), is debatable:
these definitions are adaptations from studies on virtual
colonoscopy (CT and MR colonography) where the sig-
nificance level was set at >10 mm, showing a sensitivity >
75% and specificity > 90% for both examinations[23-25].
To date, there is evidence that virtual colonoscopy is not
an accurate alternative for diagnostically relevant small
polyps[26].
Additional polyp detection (of significant size) was 4%.
We partly ascribe this to altered size estimation and mul-
tiple detection of polyps on CCE[27], and to the generally
low detection rate of significant size polyps on colonosco-
pies in our study (assumption from experience).
However, although numbers are small, CCE showed
excellent detection of significant size adenoma (tubuluar
and tubulo-villous).
From the 41/56 patients that were diagnosed positive
(polyps of any size) on colonoscopy, 6 patients had a neg-
ative CCE. Reasons for this miss rate have been discussed
above, but clearly, CCE needs improvement to the gold
standard.
Several findings on CCE (23%, all polyp size) were not
confirmed on CSPY. This could also be a false negative
rate for CSPY. As CSPY was referred to as the gold stan-
dard, we did not include a second look endoscopy to
assess this finding, nor did we analyze underlying pat-
terns why polyps were missed on CSPY.
The negative predictive value of 93% for significant pol-
yps fulfills demands for a screening exam[28], although
the meaning is altered by a PPV of 20 to 63%.
A recently published study[20] showed comparable
results for sensitivity and negative predictive value,
although patients with known history of both polyps and
colon carcinoma were included.
Second, the preparation regimen suggested by Given
Imaging has much been improved, though it still remains
more intense than bowel preparation for colonoscopy.
We found a lower excretion rate for CCE (64%, n = 36)
than the two previous pilot studies. This might be caused
by an additional fasting time of almost 4 hours between
ingestion of the second 2 liters of Macrogolum and initia-
tion of CCE, as motility studies have shown an enhanced
colonic propulsion of the capsule through PEG. Also, the
Israelian study[18] was able to use Tegaserod (Zelmac®,
Novartis, Basel, Switzerland) which in Switzerland was
discontinued in October 2001.
In our study, we found a good level of cleansing only in
37% (n = 15) patients on CCE. As we regularly use a
three-point-scale for graduation of cleansing level this
was adapted to CCE for better utility.
We also had a low percentage of good cleansing grades
for CSPY (13%, n = 7). Our results for poor bowel prepa-
ration are consistent with other reports on colon cleans-
ing, where the mean percentage of poorly cleaned bowels
varies between 20-25% (20%, n = 11, in our study)[30,31],
but in marked contrast to previous pilot studies that
showed an excellent/good cleansing level of 88%[17] resp.
84.4%[18].
Grades for cleansing on CSPY are not described in the
two mentioned pilot studies. We do explain our findings
with the altered assessment scale and, as mentioned
above, at least for CCE, with the break in between inges-
tion of the second 2 liters of PEG and ingestion of the
capsule.
Table 4: CCE: Sensitivity, Specificity, PPV and NPV for any size polyps and significant size (>5 mm) polyps
For polyps of any size For polyps >5 mm
Sensitivity % (95% CI) 79 (61 - 90) 50 (19 - 81)
Specificity % (95% CI) 54 (35 - 70) 76 (36 - 86)
Positive predictive value % 63 20
Negative predictive value % 71
Χ2: p = 0.013
93
Χ2: p > 0.05
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of-cleansing[17,18,20], however, this might be due to a
low number of patients in this subanalysis.
Bowel preparation is also crucial for an efficient
colonoscopy. Inadequate preparation correlates with
higher polyp miss rates and higher costs due to lower
completion rates with need for repeated colonos-
copy[25,11].The ideal bowel preparation for CCE is yet to
be defined, and timing seems to be important. As for
now, if preparation for capsule is more complex than for
CSPY, with the procedure itself bearing a risk of volume
overload especially in predisposed patients, how large is
the benefit of CCE?
Third, 8-10 hours of validated capsule battery duration
were not sufficient for all patients, especially those with
transit disorders. In a recent motility study for patients
with severe intestinal motor disorders, using PillCam
SB[32], it was shown, that occurrence of less contractile
activity, more static periods and also more content reten-
tion was statistically significant. Although these findings
apply to small bowel observations, it seems probable to
translate affected intestinal motility to the colon and rec-
tum, therefore emphasizing the need for a prolonged bat-
tery time.
Fourth, CCE has a good acceptance: 94% of patients (n
= 50) would recommend CCE as a screening method to
somebody who has so far rejected undergoing screening
by CSPY, and 83% (n = 44) would adhere to the suggested
screening regimen suggesting a 10-year repeat CCE.
Interestingly, on postinterventional assessment, 20
patients (38%) preferred CSPY to CCE which is contra-
dictory to preinterventional data[33-35] and might be
due to propofol usage for sedation[36].
Conclusion
In summary, PillCam Colon provides a screening solution
which is minimally invasive, safe and does not require
sedation. It is very well accepted by patients and recom-
mended to people who have so far denied CRC screening
programs. It is an easy to perform examination with an
excellent negative predictive value for application in
screening purposes under routine conditions. However,
diagnostic accuracy for relevant size polyps (i.e. sensitiv-
ity) is low. In order to have an assigned part in CRC
screening, capsule endoscopy needs to overcome its main
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Figure 2 Images of colon polyps on Colonoscopy (left) vs. CCE 
(right). A: Polyp smaller or as big as 5 mm, B, C: Polyps bigger than 5 
mm
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